Now What? Sanofi CEO Urges Incentives As China Embraces New Drugs
Executive Summary
Delinking drug approvals from price agreements, and providing timely and adequate reimbursement coverage, are just some of the policy changes top big pharma executives would like to see if China is to create an operating environment conducive to innovation.
You may also be interested in...
Catch Me If You Can: Knowing How To Innovate Matters In China
Given the host of recent and planned policy and regulatory changes in China, the traditional lines between multinational and local companies in the country will become increasingly blurred. These who know how to innovate in different ways in the fast-changing environment will have the most to gain, says the head of one major pharma industry trade group.
Sanofi's Biosimilars Deal With JHL Confirms Growing Trend In China
Sanofi is joining the biosimilars trend to tap into China through a local partnership with Taiwan's JHL Biotech, initially focusing on rituximab, a biosimilar product that has great market potential but strong competition in development by domestic peers.
Gilead Taps New Talent In China Hepatitis Drug Access Drive
In signs of a strategy shift, Gilead Sciences appears to be independently pursuing opportunities in China's rapidly growing hepatitis market by appointing a top market access executive.